Here are five points:
1. Mr. McBrayer is succeeding Kyle Kerbawy, who will retain his role as chairman of the board.
2. Mr. McBrayer has more than 20 years of senior management experience in healthcare.
3. He currently serves on the board of directors of Misonix.
4. He was also president and CEO of AxioMed Spine, until the company was acquired in 2014.
5. ACell is a regenerative medicine company focused on the development and commercialization of unique proprietary extracellular matrix products.
More articles on devices:
K2M 2015 preliminary revenue up 16%: 5 key notes
SeaSpine preliminary Q4 revenue flat at $35M: 5 key notes
NeuroMetrix estimates its 2015 Q4 revenue at $2.7M — 5 observations
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
